BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Khoja S, Huynh N, Warnecke AMP, Asatryan L, Jakowec MW, Davies DL. Preclinical evaluation of avermectins as novel therapeutic agents for alcohol use disorders. Psychopharmacology (Berl) 2018;235:1697-709. [PMID: 29500584 DOI: 10.1007/s00213-018-4869-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Volkova YA, Rassokhina IV, Kondrakhin EA, Rossokhin AV, Kolbaev SN, Tihonova TB, Kh. Dzhafarov M, Schetinina MA, Chernoburova EI, Vasileva EV, Dmitrenok AS, Kovalev GI, Sharonova IN, Zavarzin IV. Synthesis and Evaluation of Avermectin–Imidazo[1,2-a]pyridine Hybrids as Potent GABAA Receptor Modulators. Bioorganic Chemistry 2022. [DOI: 10.1016/j.bioorg.2022.105904] [Reference Citation Analysis]
2 Silva J, Carry E, Xue C, Zhang J, Liang J, Roberge JY, Davies DL. A Novel Dual Drug Approach That Combines Ivermectin and Dihydromyricetin (DHM) to Reduce Alcohol Drinking and Preference in Mice. Molecules 2021;26:1791. [PMID: 33810134 DOI: 10.3390/molecules26061791] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Warnecke AMP, Kang MS, Jakowec MW, Davies DL. The macrocyclic lactones ivermectin and moxidectin show differential effects on rotational behavior in the 6-hydroxydopamine mouse model of Parkinson's disease. Behav Brain Res 2020;393:112804. [PMID: 32668263 DOI: 10.1016/j.bbr.2020.112804] [Reference Citation Analysis]
4 El-Saber Batiha G, Alqahtani A, Ilesanmi OB, Saati AA, El-Mleeh A, Hetta HF, Magdy Beshbishy A. Avermectin Derivatives, Pharmacokinetics, Therapeutic and Toxic Dosages, Mechanism of Action, and Their Biological Effects. Pharmaceuticals (Basel) 2020;13:E196. [PMID: 32824399 DOI: 10.3390/ph13080196] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
5 Silva J, Khoja S, Asatryan L, Pacifici E, Davies DL. A novel pharmacotherapy approach using P-glycoprotein (PGP/ABCB1) efflux inhibitor combined with ivermectin to reduce alcohol drinking and preference in mice. Alcohol 2020;86:1-8. [PMID: 32278067 DOI: 10.1016/j.alcohol.2020.03.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Bragança B, Correia-de-Sá P. Resolving the Ionotropic P2X4 Receptor Mystery Points Towards a New Therapeutic Target for Cardiovascular Diseases. Int J Mol Sci 2020;21:E5005. [PMID: 32679900 DOI: 10.3390/ijms21145005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
7 Reyes-Espinosa F, Nieto-Pescador MG, Bocanegra-García V, Lozano-Guzmán E, Rivera G. In Silico Analysis of FDA Drugs as P2X4 Modulators for the Treatment of Alcohol Use Disorder. Mol Inform 2020;39:e1900111. [PMID: 32511896 DOI: 10.1002/minf.201900111] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 McKee DL, Sternberg A, Stange U, Laufer S, Naujokat C. Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacol Res. 2020;157:104859. [PMID: 32360480 DOI: 10.1016/j.phrs.2020.104859] [Cited by in Crossref: 226] [Cited by in F6Publishing: 203] [Article Influence: 113.0] [Reference Citation Analysis]
9 Getachew B, Tizabi Y. Antidepressant effects of moxidectin, an antiparasitic drug, in a rat model of depression. Behav Brain Res 2019;376:112220. [PMID: 31513828 DOI: 10.1016/j.bbr.2019.112220] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]